Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference
Kane Biotech (KNBIF) announced that Interim CEO Dr. Robert Huizinga will present clinical data for their FDA 510(k) cleared revyve® products at the Symposium on Advanced Wound Care Fall conference in Las Vegas.
Two significant case studies will be presented: The first demonstrates how revyve Antimicrobial Wound Gel successfully treated a two-year-old Stage 4 sacral ulcer, reducing pain scores from 10/10 to 0 and decreasing wound size over three weeks. The second case study shows how the gel, combined with vibrational debridement, achieved a 60% wound size reduction over eight weeks in a two-year-old venous leg ulcer, with pain scores dropping from 5/10 to 0.
Kane Biotech (KNBIF) ha annunciato che l'Amministratore Delegato ad interim, il Dr. Robert Huizinga, presenterà dati clinici sui loro prodotti revyve® autorizzati dalla FDA tramite 510(k) al Symposium on Advanced Wound Care Fall di Las Vegas.
Saranno presentati due casi clinici significativi: il primo mostra come il revyve Antimicrobial Wound Gel abbia trattato con successo un'ulcera sacrale di Stadio 4 presente da due anni, riducendo il dolore da 10/10 a 0 e diminuendo le dimensioni della ferita in tre settimane. Il secondo caso dimostra come il gel, combinato con debridement vibratorio, abbia ottenuto una riduzione del 60% della lesione in otto settimane in un'ulcera venosa alla gamba presente da due anni, con il dolore che è passato da 5/10 a 0.
Kane Biotech (KNBIF) anunció que el CEO interino, el Dr. Robert Huizinga, presentará datos clínicos de sus productos revyve® aprobados por la FDA mediante 510(k) en el Symposium on Advanced Wound Care Fall en Las Vegas.
Se expondrán dos estudios de caso relevantes: el primero demuestra cómo el revyve Antimicrobial Wound Gel trató con éxito una úlcera sacra en etapa 4 de dos años de evolución, reduciendo el dolor de 10/10 a 0 y disminuyendo el tamaño de la herida en tres semanas. El segundo muestra cómo el gel, combinado con desbridamiento vibratorio, logró una reducción del 60% en el tamaño de la herida en ocho semanas en una úlcera venosa de la pierna de dos años de evolución, con el dolor bajando de 5/10 a 0.
Kane Biotech (KNBIF)는 임시 CEO인 로버트 하이징가 박사가 라스베이거스에서 열리는 Symposium on Advanced Wound Care Fall 컨퍼런스에서 FDA 510(k) 승인을 받은 revyve® 제품의 임상 데이터를 발표할 것이라고 밝혔습니다.
두 건의 주요 사례가 발표됩니다. 첫 번째는 revyve Antimicrobial Wound Gel이 2년 된 4단계 천골 궤양을 성공적으로 치료하여 통증 점수를 10/10에서 0으로 낮추고 3주 만에 상처 크기를 줄인 사례입니다. 두 번째 사례는 젤을 진동형 데브리드먼트와 병용해 2년 된 하지 정맥성 궤양에서 8주 동안 상처 크기 60% 감소를 달성하고 통증 점수가 5/10에서 0으로 떨어진 사례를 보여줍니다.
Kane Biotech (KNBIF) a annoncé que le directeur général par intérim, le Dr Robert Huizinga, présentera des données cliniques concernant leurs produits revyve® homologués par la FDA via 510(k) au Symposium on Advanced Wound Care Fall à Las Vegas.
Deux études de cas importantes seront présentées : la première montre comment le revyve Antimicrobial Wound Gel a traité avec succès un ulcère sacral de stade 4 datant de deux ans, réduisant la douleur de 10/10 à 0 et diminuant la taille de la plaie en trois semaines. La deuxième étude montre comment le gel, associé à un débridement vibratoire, a permis une réduction de 60% de la taille de la plaie en huit semaines pour un ulcère veineux de la jambe présent depuis deux ans, la douleur passant de 5/10 à 0.
Kane Biotech (KNBIF) gab bekannt, dass der Interim-CEO Dr. Robert Huizinga klinische Daten zu ihren FDA 510(k)-zugelassenen revyve® Produkten auf dem Symposium on Advanced Wound Care Fall in Las Vegas vorstellen wird.
Es werden zwei bedeutende Fallstudien präsentiert: Die erste zeigt, wie das revyve Antimicrobial Wound Gel ein zweijähriges Ulkus sacrum Stadium 4 erfolgreich behandelte, die Schmerzwerte von 10/10 auf 0 senkte und die Wundgröße innerhalb von drei Wochen verringerte. Die zweite Fallstudie demonstriert, wie das Gel in Kombination mit vibrationaler Débridement eine Wundgrößenreduktion von 60% innerhalb von acht Wochen bei einem zweijährigen venösen Beingeschwür erreichte, wobei die Schmerzwerte von 5/10 auf 0 fielen.
- None.
- None.
Clinical data to be presented demonstrates wound healing in complex wounds that were over two years old
WINNIPEG, Manitoba, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the Symposium on Advanced Wound Care (“SAWC”) Fall conference taking place from September 3-6, 2025 in Las Vegas, Nevada.
US FDA 510(k) cleared revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray
SAWC is a multidisciplinary community of wound care professionals — including physicians, nurses, podiatrists, physical therapists, researchers, administrators and wound care companies — that share the latest evidence-based practices, clinical innovations, and research aimed at improving outcomes in wound management.
Two presentations are being given at this meeting:
In this case study, revyve Antimicrobial Wound Gel was used on a two-year old non-healing Stage 4 sacral ulcer and a pain score of 10/10 in an elderly patient. Previous treatment included daily dressing changes using silver-based antimicrobial agents, gelling fibre wound fillers. This was a deep cavity wound requiring a thermoreversible gel to cover all of the wound surface. Use of revyve and daily dressing changes resulted in pain scores of 0, and wound size was decreased over three weeks. A reduction in Klebsiella pneumonia cultures was noted over the course of treatment. The patient remained on dressing changes with revyve over the two-month course of the study.
In this case study, revyve Antimicrobial Wound Gel along with a vibrational debridement tool was used on an elderly female with a two-year old non-healing venous leg ulcer. This was a full thickness wound with slough, eschar and necrotic tissue present, alongside granulation tissue. Pain score was 5/10. Pain levels decreased with dressing changes, with the patient reporting a score of 0 from Week three onward. The wound showed progressive healing with a wound size reduction of
Kane’s US Food and Drug Administration (FDA) 510(k) cleared revyve Antimicrobial Wound Gel and Wound Gel Spray products will be exhibited at the conference. Dr. Huizinga will also be meeting with potential US distributors.
About Kane Biotech Inc. (TSX-V: KNE)
Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve® addresses both biofilms and wound bacteria. revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray are US FDA 510(k) cleared. revyve® Antimicrobial Wound Gel is Health Canada approved. To learn more about revyve, visit revyvegel.com or revyvegel.ca.
Join Kane’s Distribution List & Social Media:
To stay informed on the latest developments, sign-up for the Company’s email distribution list HERE.
Follow Kane
Website: kanebiotech.com
LinkedIn: https://www.linkedin.com/company/kanebiotech/
| For more information: | ||
| Dr. Robert Huizinga | Ray Dupuis | |
| Interim CEO | Chief Financial Officer | |
| Kane Biotech Inc. | Kane Biotech Inc. | |
| rhuizinga@kanebiotech.com | rdupuis@kanebiotech.com | |
| (780) 970-1100 | (204) 298-2200 | |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar+.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bd2cf932-40cc-4466-abbe-4bdc61611b29
FAQ
What clinical results did Kane Biotech (KNBIF) present for revyve® at SAWC 2025?
What is the regulatory status of Kane Biotech's revyve® wound products?
How effective was revyve® in reducing wound pain in clinical studies?
What types of wounds were successfully treated with Kane Biotech's revyve®?
When and where is Kane Biotech presenting the revyve® clinical data?
